Imatinib Koanaa 400 Mg

Imatinib, the active ingredient in Imatinib Koanaa 400 Mg, is a tyrosine kinase inhibitor presented as a 400 mg tablet for oral use. It treats chronic myeloid leukemia, Philadelphia chromosome‑positive acute lymphoblastic leukemia, and gastrointestinal stromal tumor in adult patients, targeting malignant cell proliferation. The drug is approved in the European Union and is used under prescription by qualified healthcare professionals.

GNH USA supplies Imatinib Koanaa 400 Mg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, with established distribution networks and regulatory expertise across multiple regions.

Imatinib is a targeted tyrosine‑kinase inhibitor used in hematologic and solid‑tumor oncology.

- Chronic myeloid leukemia (CML): reduces leukemic cell proliferation and helps achieve durable molecular remission. - Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): improves survival by inhibiting BCR‑ABL driven growth. - Gastrointestinal stromal tumor (GIST): controls tumor growth by blocking c‑KIT and PDGFR signaling.

Imatinib may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: watery stools, often transient. - Edema: peripheral swelling, especially of ankles. - Fatigue: generalized tiredness.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or liver injury. - Myelosuppression: neutropenia, anemia, thrombocytopenia. - Cardiotoxicity: congestive heart failure or reduced ejection fraction.

Patients receiving Imatinib should be monitored regularly for safety and efficacy. - Monitor blood counts: regular CBC to detect myelosuppression. - Assess liver function: periodic LFTs for hepatotoxicity. - Evaluate cardiac status: baseline and periodic echocardiograms in at‑risk patients. - Avoid use in patients with known hypersensitivity to imatinib or its excipients. - Counsel on pregnancy risks: discuss potential fetal harm and contraception. - Store at below 25°C: keep in the original container, protect from moisture and light.

Imatinib can interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce imatinib exposure. - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): can increase plasma levels and toxicity. - Antacids containing aluminum or magnesium: may decrease absorption if taken simultaneously.

Moderate Interactions (Monitor Closely): - Warfarin: imatinib may enhance anticoagulant effect, monitor INR. - Phenytoin: may alter imatinib metabolism, monitor therapeutic levels. - Live attenuated vaccines: potential reduced efficacy, consider timing of administration.